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Inhibition of T-Cell Function by FK 506 and Cyclosporine Is Not 
Accompanied by Alterations in Intracellular Calcium 
M.L. Jordan, S. Hignet, J. Wright, R.A. Hoffman, and T.E. Starzl 
FK 506 is a novel immunosuppressant that is more potent than cyclosporine (CyA) and has been used 
with encouraging results in preliminary clinical trials of 
organ transplantation. l -4 FK 506 is a macrolide whereas 
Cy A is a cyclic peptide. Despite their structural differences 
and the fact that FK 506 and CyA bind to different 
cytosolic peptidyl-prolyl isomerases (PPIases), both 
agents have shown remarkably similar qualitative effects 
on in vitro T-cell function. ~ Both FK 506 and Cy A inhibit 
interleukin-2 (lL-2) , IL-3, IL-4, tumor necrosis factor 
alpha (TNF-a), and interferon gamma (INF-'Y) synthesis as 
well as the mRNA levels of these cytokines during T-cell 
activation.5- 9 Although these mechanisms may involve 
calcium-dependent pathways, it is unclear whether FK 506 
and Cy A actually alter signal transduction via changes in 
intracellular calcium ([Ca2 +]i)' Since FK 506 and CyA 
possess distinct cytosolic binding sites. it is conceivable 
that intracellular signaling via second messengers may be 
differentially affected by these two agents. Such differ-
ences could have important consequences in their mecha-
nism of immunosuppression. The purpose of this study 
was to determine whether [Ca2 +]i is involved in the 
suppression of T-cell function by FK 506 and CyA. 
MATERIALS AND METHODS 
Animals 
Female C57BU6 (B6, H-2b) and DBAl2J (DBA, H_2d) mice were 
purchased from the Jackson Laboratory, Bar Harbor, Me. Mice 
were housed in plastic cages, provided with Purina Rodent Chow 
and tap water ad libitum, and used at 10 to 16 weeks of age. 
Cells 
Allosensitized T cells were derived from a day 7-10 B6 anti-DBA 
mixed leukocyte culture E~iCF as previously de~cribedK 10 
Ca2 +1 Determinations 
After washing three times, 2 x 10' MLC cells were loaded with 
the Ca2+ -sensitive ftuorescent indicator Indo-I (2 lAffioUL) for 30 
minutes and both baseline and stimulated (2 ,.,.wmL concanavalin 
A [Con AD [Ca2+]i was measured in a Shimadzu RF5000 ftuores-
cence spectrophotometer, as previously described." FK 506, 
Cy A, or the approprjate vehicle control was added to the cell 
suspensions with or without Con A. 
Assessment of Proliferation 
In order to correlate potential changes [Ca2+]i with concomitant 
alterations in T-cell function, proliferation eHTdR uptake) in 
response to Con A (l ,.,.wmL) was also determined. Briefty, MLC 
cells (20,000 cells/well) were incubated in a final volume of 0.2 ml 
Dulbecco's Modified Eagle's Medium (DMEM) in triplicate fiat-
bottomed microtiter wells for 24 hours and pulsed with 2 ~Ci 
)HTdRlweli for the final 6.5 hours of the incubation period. Plates 
were then harvested onto glass fiber filter paper and the 3HTdR 
determined by liquid scintillation spectrophotometry, as previ-
ously described. I\, 
Data Analysis 
The data shown represent the mean ± SEM of results from three 
experiments. 
RESULTS 
As shown in Fig I, both FK 506 and Cy A inhibited MLC 
cell proliferation to Con A in a dose-dependent manner. 
FK 506 was approximately lOO-fold more potent than CyA 
in this regard. In further experiments, FK 506 and Cy A 
also inhibited MLC cell proliferation to monoclonal anti-
body (MAb) to CD3 (data not shown). In contrast, neither 
FK 506 nor Cy A had any effect on either baseline or Con 
A-stimulated increases in [Ca2+1, even at the highest 
doses tested (Fig 2). This held true when the drugs were 
added just before Con A as well as simultaneously or 
following Con A. Cell viability was unaffected by 24 hour 
exposure of MLC cells to the highest concentrations of FK 
506 (10.0 ng/mL) or CyA (1,000.0 ng/mL) tested as deter-
mined by trypan blue exclusion. 
DISCUSSION 
We and others have previously shown that T-cell activa-
tion by mitogen is accompanied by an elevation in 
[Ca2+1i' 11-14 This is true both for unsensitized and allosen-
sitized T cells. 11 In previous work, we have observed that 
increases in basal [Ca2+]i occur prior to maximal allosen-
sitized T-cell proliferation in culture after antigen exposure 
but that even higher [Ca2+]; levels are detected well after 
the completion of DNA synthesis. I I This raises the ques-
tion of whether [Ca2+]i may be a marker of the allosensi-
tized state and whether elevated [Ca2+l; is in fact required 
for optimal T-cell function. It is tempting to speculate that 
[Ca2+]i may play an important role in maintaining or 
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Fig 1. FK 506 and CyA inhibit Con A-induced T-cell proliferation. 
Twenty-thousand cells derived from a day 7-9 MLC were cultured 
in the presence or absence of various concentrations of the 
indicated drug. The 3HTdR uptake was determined after 24 hours. 
Data represent the mean :!: SEM of results from three experi-
ments. 
altering T-cell function within the allograft. It therefore 
became of interest to us to determine whether the immu-
nosuppressive agents FK 506 and Cy A. in addition to their 
inhibitory effects on T-cell proliferation and lymphokine 
synthesis. were capable of altering T-cell [Ca2 +li. At the 
concentrations of FK 506 and CyA that inhibit Con A-in-
duced proliferation of allosensitized MLC cells. we failed 
to observe any inhibition of the rise in [Ca2 +l; induced by 
triggering the TcR-CD3 complex with Con A. In subse-
quent experiments. we have also found that the rise in 
[Ca2+li is preserved even following a 2-hour preincubation 
with either FK 506 or Cy A. 
Thus. even though it has been shown that FK 506 and 
Cy A inhibit certain T-cell activation steps that are calcium-
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Fig 2. Effects of FK 506 and CyA on T-cell calcium signaling. 2 
x 106 day 7-9 MLC cells were loaded with indo-l (2 ILmolll) for 30 
minutes and basal (rn) and Con A-stimulated (.) [Ca2 +1i deter-
mined by fluorescence spectrophotometry. Data represent the 
mean ± SEM of results from three experiments. 
dependent.6 •15-19 these agents in and of themselves do not 
appear to alter calcium fluxes in allosensitized murine T 
cells. Similar observations have been made in human 
tumor cell lines that are not allosensitized. 18 It would 
appear that FK 506 and CyA inhibit T-cell function subse-
quent to the rise in [Ca2+l; that accompanies T-cell activa-
tion via the TcR-CD3 complex. Another novel immuno-
suppressive agent. rapamycin. appears to affect even later 
events during T-cell activation.6•2o We have not yet tested 
the effects of rapamycin on allosensitized T-cell calcium 
signaling. However, the observation that the calcium sig-
nal is preserved in the presence of FK 506 and Cy A 
suggests that potential synergism of these drugs with 
agents inhibiting [Ca2+l; may exist. 
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